Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early eating study for diabetes ends early

NCT ID NCT06887543

Knowledge-focused Sponsor: Rockefeller University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating most calories before 2 PM could help control blood sugar in people with type 2 diabetes. It planned to enroll 10 participants but was terminated after only 2 joined. The goal was to compare early eating with a typical eating pattern over six days each.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

May 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-75 able to give consent 2. BMI \>25 kg/m2 3. Hemoglobin A1C ≥ 6.5% 4. Willing to eat only the food provided 5. Willing to follow the feeding schedule, including fasting for 16 hours/day for six days. 6. Usual sleep time is between 10 PM and 8 AM 7. Fluent in the English language Exclusion Criteria: 1. Current use of anti-obesity medications (Ozempic, Mounjaro, Trulicity, Wegovy, Zepbound, Qsymia, Contrave, Saxenda, Victoza, Orlistat) 2. Report history of Cirrhosis 3. HIV positive 4. Self-reported autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, etc.) 5. Current use of steroids (inhalers are permissible) 6. Currently pregnant 7. Smoked tobacco within the last 3 months 8. Allergy to adhesive tape 9. Skips breakfast 10. Followed TRF or intermittent fasting in the last 2 weeks 11. Shift or night worker 12. Current use of insulin 13. Current use of sulfonylureas 14. Current use of glucagon-like peptide-1 (GLP-1) receptor agonists 15. Hemoglobin A1c \>8% 16. Unable to sync smartphone with Bluetooth for scale data 17. Any medical, psychological, or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Intermittent Fasting type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • The Rockefeller University Hospital

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.